MedPath

User Acceptability of a Device-Based Opioid Overdose Intervention

Completed
Conditions
Substance Use Disorders
Opioid Overdose
Opioid-use Disorder
Registration Number
NCT04530591
Lead Sponsor
University of Pennsylvania
Brief Summary

This pilot study evaluates the needs of opioid users for a device-based intervention for opioid overdoses. The results of this one-time short questionnaire will inform development of a novel naloxone delivery device.

Detailed Description

All opioid overdose related deaths can be prevented with the timely delivery of Naloxone. This study is a one-time, preliminary survey of participants with opioid use disorder to assess the need for, and community attitudes towards, a wearable device capable of autonomously detecting and responding to an opioid overdose. The results of this survey will be used to guide ongoing development of a de novo device. This study will be conducted over a 3 month period and survey participants from the Kensington Neighborhood in North Philadelphia.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
97
Inclusion Criteria
  • Have used opioids for more than 3 months or will be having surgery where opioids will be administered

    • Able to provide informed consent
    • Moderate to severe chronic pain treated with opioids or recreational use
Exclusion Criteria
  • Pregnancy

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Community Need for a Device-based Opioid Overdose InterventionDay 1

We aim to characterize the degree of need for a device-based opioid overdose intervention. These were extracted from the participant survey questions as well as from the words, phrases, and sentences used by participants during the interview.

Secondary Outcome Measures
NameTimeMethod
Functional and Aesthetic Preferences for Device-based Opioid Overdose InterventionDay 1

We aim to characterize the functional and aesthetic preferences of the participant population for a device-based opioid overdose intervention. These were extracted from the participant survey questions as well as from the words, phrases, and sentences used by participants during the interview.

Trial Locations

Locations (1)

Prevention Point Philadelphia

🇺🇸

Philadelphia, Pennsylvania, United States

Prevention Point Philadelphia
🇺🇸Philadelphia, Pennsylvania, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.